The incidence and risk of cutaneous toxicities associated with dabrafenib in melanoma patients: a systematic review and meta-analysis

In this analysis (20 trials; n=3359), the most frequent cutaneous adverse reactions included rash (30%; 95% CI 7-71%), cutaneous squamous-cell carcinoma (16%; 11-24%), alopecia (21%; 11-37%), keratoacanthoma (20%; 12-31%), hyperkeratosis (14%; 9-22%) and pruritus (8%; 5-12%).

European Journal of Hospital Pharmacy